IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
31.85
-1.75 (-5.21%)
Apr 21, 2026, 9:44 AM EDT - Market open
IDEAYA Biosciences Revenue
In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth. IDEAYA Biosciences had revenue of $10.88M in the quarter ending December 31, 2025, with 55.37% growth.
Revenue (ttm)
$218.71M
Revenue Growth
+3,024.43%
P/S Ratio
13.49
Revenue / Employee
$1,508,345
Employees
145
Market Cap
2.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 460.16M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| Beam Therapeutics | 139.74M |
| Nektar Therapeutics | 55.23M |
| Relay Therapeutics | 15.36M |
IDYA News
- 8 days ago - Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results - Barrons
- 8 days ago - IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PRNewsWire
- 10 days ago - IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - PRNewsWire
- 15 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - PRNewsWire
- 22 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma - PRNewsWire
- 25 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - PRNewsWire